Track PROCEPT BioRobotics Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

PROCEPT BioRobotics Corporation Common Stock PRCT · Stock Open PROCEPT BioRobotics Corporation Common Stock in new tab

23.80 USD
EPS
-2.02
P/B
4.06
ROE
-32.39
Beta
0.84
Target Price
22.75 USD
PROCEPT BioRobotics Corporation Common Stock logo

PROCEPT BioRobotics Corporation Common Stock

🧾 Earnings Recap – Q2 2026

Shares rose 5.2% post-earnings, reflecting market approval of stronger-than-expected system demand, notably robust HYDROS placements, and disciplined pricing that drove higher average selling prices.

  • Total revenue reached $94.5 million, up 19% year-over-year.
  • Procedure volume grew 21% to over 13,100 U.S. procedures; however, growth was softer than anticipated, driven by weaker legacy AQUABEAM account performance.
  • HYDROS system placements were strong with 65 units placed, including 50 new installs and 14 replacements, underscoring successful rollout efforts.
  • HYDROS average selling price increased to approximately $495,000, up from $485,000 in Q1 and $435,000 in full-year 2025.
  • Strategic commercial initiatives such as salesforce realignment, replacement upgrades, and patient activation pilots are underway to support sustainable growth.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-2.02
Book Value5.73
Price to Book4.06
Debt/Equity23.41
% Insiders3.464%
Growth
Revenue Growth0.18%
Estimates
Forward P/E-18.91
Forward EPS-1.23
Target Mean Price22.75

DCF valuation

Model fair value for PROCEPT BioRobotics Corporation Common Stock (PRCT)
Result
Sign in to run the valuation for PRCT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
12 analysts · consensus Hold · mean target 22.75 USD (low 16.00, high 30.00) · as of 12 Nov 2026
Low 16.00
Mean 22.75
High 30.00
Price 23.80
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

PROCEPT BioRobotics Corporation Common Stock Logo PROCEPT BioRobotics Corporation Common Stock Analysis (PRCT)

United States Health Care Official Website Stock

Is PROCEPT BioRobotics Corporation Common Stock a good investment? PROCEPT BioRobotics Corporation Common Stock (PRCT) is currently trading at 23.80 USD. Market analysts have a consensus price target of 22.75 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: PROCEPT BioRobotics Corporation Common Stock is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -1.23.

Investor FAQ

Does PROCEPT BioRobotics Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is PROCEPT BioRobotics Corporation Common Stock?

PROCEPT BioRobotics Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -2.02.

Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Exchange Ticker
NMS (United States) PRCT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion